Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback